Nothing Special   »   [go: up one dir, main page]

BR112018072195A2 - amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer - Google Patents

amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer

Info

Publication number
BR112018072195A2
BR112018072195A2 BR112018072195-6A BR112018072195A BR112018072195A2 BR 112018072195 A2 BR112018072195 A2 BR 112018072195A2 BR 112018072195 A BR112018072195 A BR 112018072195A BR 112018072195 A2 BR112018072195 A2 BR 112018072195A2
Authority
BR
Brazil
Prior art keywords
moma
multiplex
real time
time pcr
mismatch amplification
Prior art date
Application number
BR112018072195-6A
Other languages
English (en)
Inventor
Tomita Mitchell Aoy
Stamm Karl
Original Assignee
The Medical College Of Wisconsin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medical College Of Wisconsin, Inc. filed Critical The Medical College Of Wisconsin, Inc.
Publication of BR112018072195A2 publication Critical patent/BR112018072195A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

esta invenção refere-se a métodos e composições para avaliar uma quantidade de ácidos nucleicos específicos de câncer em uma amostra, tal como de um sujeito. os métodos e composições aqui fornecidos podem ser utilizados para determinar o risco de uma condição, tal como câncer em um indivíduo.
BR112018072195-6A 2016-04-29 2017-04-29 amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer BR112018072195A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330043P 2016-04-29 2016-04-29
US62/330,043 2016-04-29
PCT/US2017/030291 WO2017190104A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer

Publications (1)

Publication Number Publication Date
BR112018072195A2 true BR112018072195A2 (pt) 2019-02-12

Family

ID=58709564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072195-6A BR112018072195A2 (pt) 2016-04-29 2017-04-29 amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer

Country Status (11)

Country Link
US (1) US20200181681A1 (pt)
EP (1) EP3449014A1 (pt)
JP (2) JP2019518437A (pt)
CN (1) CN109715826A (pt)
AU (1) AU2017258799A1 (pt)
BR (1) BR112018072195A2 (pt)
CA (1) CA3022545A1 (pt)
EA (1) EA201892491A1 (pt)
IL (1) IL262640A (pt)
MX (1) MX2018013223A (pt)
WO (1) WO2017190104A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP3294906B1 (en) 2015-05-11 2024-07-10 Natera, Inc. Methods for determining ploidy
AU2017355458A1 (en) * 2016-11-02 2019-06-13 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
JP2021506342A (ja) 2017-12-14 2021-02-22 ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 移植のための移植片適合性の評価
EP3781714A1 (en) 2018-04-14 2021-02-24 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
JP2002513402A (ja) 1997-02-25 2002-05-08 アリゾナ ボード オブ リーゼンツ 細胞増殖抑制性の鎖状および環状デプシペプチドであるドラスタチン１６、ドラスタチン１７およびドラスタチン１８の単離と構造決定
US20030148301A1 (en) * 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
JP4116856B2 (ja) * 2002-10-02 2008-07-09 富士フイルム株式会社 １塩基多型の検出方法
WO2011118603A1 (ja) * 2010-03-24 2011-09-29 凸版印刷株式会社 競合プライマーによる標的塩基配列の検出方法
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
US20140242582A1 (en) 2013-02-28 2014-08-28 Ariosa Diagnostics, Inc. Detection of genetic abnormalities using ligation-based detection and digital pcr
DK3194612T3 (da) * 2014-08-22 2024-10-14 Resolution Bioscience Inc Fremgangsmåder til kvantitativ genetisk analyse af cellefrit dna
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Also Published As

Publication number Publication date
MX2018013223A (es) 2019-04-22
CA3022545A1 (en) 2017-11-02
JP2019518437A (ja) 2019-07-04
EA201892491A1 (ru) 2019-06-28
IL262640A (en) 2018-12-31
WO2017190104A1 (en) 2017-11-02
AU2017258799A1 (en) 2018-12-20
EP3449014A1 (en) 2019-03-06
JP2022084647A (ja) 2022-06-07
CN109715826A (zh) 2019-05-03
US20200181681A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
BR112018072195A2 (pt) amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer
BR112018072196A2 (pt) amplificação de incompatibilidade otimizada multiplexadas (moma) - número do alvo
BR112017023232A2 (pt) pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células
MX2018013261A (es) Reacción de cadena de polimerasas para amplificación de discordancias optimizada multiplicada (moma)-en tiempo real para la valoración del bienestar fetal.
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
BR112017020054A2 (pt) anticorpos para icos
DK3583214T5 (da) Fremgangsmåder og sammensætninger til identificering eller kvantificering af mål i en biologisk prøve
BR112018010430A2 (pt) composições bacterianas projetadas
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
EP3389481A4 (en) PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
BR112017024747A2 (pt) composições e métodos para enriquecer populações de ácidos nucleicos
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
BR112019010342A2 (pt) composições do irna de serpina1 e métodos de uso destas
IN2014DN08831A (pt)
BR112019005748A2 (pt) afinidade-conjugados de oligonucleotídeo e usos destes
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
BR112018015965A2 (pt) método para determinação de helicobacter pylori
MX2021000899A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
CO2018007621A2 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer
GB2576836B (en) Compositions and methods for multiplexed quantitative analysis of cell lineages
BR112016024622A2 (pt) composições e métodos para melhorar e/ou prever a amplificação de dna
ZA202101476B (en) Methods and compositions for nucleic acid isolation

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.